Northeast Pharmaceutical Group Co Ltd (SHE:000597) — Market Cap & Net Worth
Market Cap & Net Worth: Northeast Pharmaceutical Group Co Ltd (000597)
Northeast Pharmaceutical Group Co Ltd (SHE:000597) has a market capitalization of $973.03 Million (CN¥6.65 Billion) as of September 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #9088 globally and #2246 in its home market, demonstrating a -3.12% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Northeast Pharmaceutical Group Co Ltd's stock price CN¥4.66 by its total outstanding shares 1426928265 (1.43 Billion). Also see Northeast Pharmaceutical Group Co Ltd assets under control for a full breakdown of the balance sheet.
Northeast Pharmaceutical Group Co Ltd Market Cap History: 2015 to 2026
Northeast Pharmaceutical Group Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $933.42 Million to $973.03 Million (2.51% CAGR). Also see 000597 cash flow conversion for how efficiently the company converts equity into cash flow.
Northeast Pharmaceutical Group Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Northeast Pharmaceutical Group Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check current stock price of Northeast Pharmaceutical Group Co Ltd for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.15x
Northeast Pharmaceutical Group Co Ltd's market cap is 0.15 times its annual revenue
Latest Price to Earnings (P/E) Ratio
4.19x
Northeast Pharmaceutical Group Co Ltd's market cap is 4.19 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $900.09 Million | $4.81 Billion | $23.79 Million | 0.19x | 37.84x |
| 2017 | $1.06 Billion | $5.68 Billion | $119.00 Million | 0.19x | 8.90x |
| 2018 | $914.50 Million | $7.47 Billion | $195.20 Million | 0.12x | 4.68x |
| 2019 | $1.00 Billion | $8.22 Billion | $173.98 Million | 0.12x | 5.75x |
| 2020 | $1.01 Billion | $7.38 Billion | $12.26 Million | 0.14x | 82.66x |
| 2021 | $1.24 Billion | $8.15 Billion | $99.03 Million | 0.15x | 12.57x |
| 2022 | $1.27 Billion | $8.81 Billion | $350.25 Million | 0.14x | 3.62x |
| 2023 | $1.09 Billion | $8.24 Billion | $358.46 Million | 0.13x | 3.05x |
| 2024 | $1.10 Billion | $7.50 Billion | $409.85 Million | 0.15x | 2.68x |
| 2025 | $1.09 Billion | $7.07 Billion | $260.07 Million | 0.15x | 4.19x |
Competitor Companies of 000597 by Market Capitalization
Companies near Northeast Pharmaceutical Group Co Ltd in the global market cap rankings as of September 19, 2026. Review 000597 goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Northeast Pharmaceutical Group Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #613 globally with a market cap of $44.92 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #613 | GALDERMA GROUP AG | NYSE:GALDY | $44.92 Billion | $38.53 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
Northeast Pharmaceutical Group Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Northeast Pharmaceutical Group Co Ltd's market cap moved from $933.42 Million to $ 973.03 Million, with a yearly change of 2.51%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥973.03 Million | -10.73% |
| 2025 | CN¥1.09 Billion | -0.95% |
| 2024 | CN¥1.10 Billion | +0.66% |
| 2023 | CN¥1.09 Billion | -13.67% |
| 2022 | CN¥1.27 Billion | +1.71% |
| 2021 | CN¥1.24 Billion | +22.88% |
| 2020 | CN¥1.01 Billion | +1.26% |
| 2019 | CN¥1.00 Billion | +9.40% |
| 2018 | CN¥914.50 Million | -13.61% |
| 2017 | CN¥1.06 Billion | +17.60% |
| 2016 | CN¥900.09 Million | -3.57% |
| 2015 | CN¥933.42 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Northeast Pharmaceutical Group Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $973.03 Million USD |
| MoneyControl | $973.03 Million USD |
| MarketWatch | $973.03 Million USD |
| marketcap.company | $973.03 Million USD |
| Reuters | $973.03 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Northeast Pharmaceutical Group Co Ltd
Northeast Pharmaceutical Group Co., Ltd. engages in chemical pharmaceuticals manufacturing, pharmaceutical distribution, pharmaceutical engineering, biopharmaceuticals, and other businesses in China. It offers vitamin products, such as vitamin C, vitamin B1, vitamin B6, and L-carnitine series; anti- infective products, such as fosfomycin series, azithromycin series, amantadine series, polyalkali … Read more